FindTrial
Sign In

Luteal Phase Commencing of Growth Hormone

Growth Hormone co-Treatment Within a GnRH Agonist Long Protocol in Patients With Poor Ovarian Response

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00561769
Enrollment
61
Registered
2007-11-21
Start date
2005-01-31
Completion date
2007-11-30
Last updated
2007-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

poor responder, growth hormone, luteal

Brief summary

Commencing of growth hormone in luteal phase when follicular cohort for the next cycle is being gathered may increase mature oocytes in poor responder

Interventions

DRUGNorditropin pen

12 IU per day

Sponsors

Ren-Tıp ART Center, Bursa, Turkey
CollaboratorUNKNOWN
Gulhane School of Medicine
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Poor responder

Exclusion criteria

* FSH \>20 IU

Design outcomes

Primary

MeasureTime frame
mature oocyte number2 years

Secondary

MeasureTime frame
pregnancy rate2 years

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026